Over the past decade, the development of cutting-edge technologies, including Next Generation Sequencing (NGS), has allowed to pinpoint genetic germline variants in 16–21% of t-MN patients, including inherited mutations in certain cancer-related genes, such as BARD1, BRCA1, BRCA2, CHEK2, TP53, as well as variants in the Fanconi Anemia pathway (FANCA, FANCD2, FANCJ and PALB2) [17,18,19,20]. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.